Nektar Therapeutics (NKTR) stock
NKTRNasdaqPharmaceutical PreparationsFiscal year ends December 31
$35.91−0.53 (-1.45%)
Close on Nov 17, 2026Market cap $1.23BP/E –Yield –
Nektar Therapeutics gross margin
Gross margin is gross profit as a percentage of revenue.
Nektar Therapeutics's gross margin for the twelve months ending Dec 31, 2025 was 100.0%. For fiscal 2025 it was 100.0%, against 68.8% the year before. The highest annual figure on record is 100.0% in fiscal 2025.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 100.0% | +31.2 |
| FY2024 | Dec 31, 2024 | 68.8% | +6.3 |
| FY2023 | Dec 31, 2023 | 62.5% | −14.0 |
| FY2022 | Dec 31, 2022 | 76.5% | +0.9 |
| FY2021 | Dec 31, 2021 | 75.6% | −11.7 |
| FY2020 | Dec 31, 2020 | 87.3% | +5.9 |
| FY2019 | Dec 31, 2019 | 81.4% | −16.6 |
| FY2018 | Dec 31, 2018 | 98.0% | +7.9 |
| FY2017 | Dec 31, 2017 | 90.1% | +8.3 |
| FY2016 | Dec 31, 2016 | 81.7% | −3.5 |
| FY2015 | Dec 31, 2015 | 85.2% | −0.6 |
| FY2014 | Dec 31, 2014 | 85.8% | +11.6 |
| FY2013 | Dec 31, 2013 | 74.1% | +11.6 |
| FY2012 | Dec 31, 2012 | 62.5% | −6.9 |
| FY2011 | Dec 31, 2011 | 69.4% | −14.5 |
| FY2010 | Dec 31, 2010 | 83.9% | +26.9 |
| FY2009 | Dec 31, 2009 | 57.0% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | 100.0% | +27.3 |
| Q3 FY2025 | Sep 30, 2025 | 100.0% | +18.4 |
| Q2 FY2025 | Jun 30, 2025 | 100.0% | +41.5 |
| Q1 FY2025 | Mar 31, 2025 | 100.0% | +39.4 |
| Q4 FY2024 | Dec 31, 2024 | 72.7% | +3.2 |
| Q3 FY2024 | Sep 30, 2024 | 81.6% | +33.1 |
| Q2 FY2024 | Jun 30, 2024 | 58.5% | −7.3 |
| Q1 FY2024 | Mar 31, 2024 | 60.6% | −6.7 |
| Q4 FY2023 | Dec 31, 2023 | 69.5% | −2.2 |
| Q3 FY2023 | Sep 30, 2023 | 48.5% | −30.4 |
| Q2 FY2023 | Jun 30, 2023 | 65.9% | −10.4 |
| Q1 FY2023 | Mar 31, 2023 | 67.3% | −11.3 |
| Q4 FY2022 | Dec 31, 2022 | 71.7% | −3.7 |
| Q3 FY2022 | Sep 30, 2022 | 79.0% | +0.3 |
| Q2 FY2022 | Jun 30, 2022 | 76.3% | +3.4 |
| Q1 FY2022 | Mar 31, 2022 | 78.6% | +2.9 |
| Q4 FY2021 | Dec 31, 2021 | 75.4% | −6.2 |
| Q3 FY2021 | Sep 30, 2021 | 78.7% | −2.8 |
| Q2 FY2021 | Jun 30, 2021 | 72.9% | −15.2 |
| Q1 FY2021 | Mar 31, 2021 | 75.7% | −16.8 |
| Q4 FY2020 | Dec 31, 2020 | 81.6% | −0.7 |
| Q3 FY2020 | Sep 30, 2020 | 81.5% | −1.7 |
| Q2 FY2020 | Jun 30, 2020 | 88.2% | +9.7 |
| Q1 FY2020 | Mar 31, 2020 | 92.5% | +11.7 |
| Q4 FY2019 | Dec 31, 2019 | 82.3% | +1.0 |
| Q3 FY2019 | Sep 30, 2019 | 83.1% | +0.4 |
| Q2 FY2019 | Jun 30, 2019 | 78.5% | −21.0 |
| Q1 FY2019 | Mar 31, 2019 | 80.7% | −1.8 |
| Q4 FY2018 | Dec 31, 2018 | 81.3% | −8.5 |
| Q3 FY2018 | Sep 30, 2018 | 82.8% | −13.5 |
| Q2 FY2018 | Jun 30, 2018 | 99.5% | +25.5 |
| Q1 FY2018 | Mar 31, 2018 | 82.5% | +7.3 |
| Q4 FY2017 | Dec 31, 2017 | 89.8% | +7.4 |
| Q3 FY2017 | Sep 30, 2017 | 96.3% | +15.6 |
| Q2 FY2017 | Jun 30, 2017 | 74.0% | −2.5 |
| Q1 FY2017 | Mar 31, 2017 | 75.2% | – |
| Q4 FY2016 | Dec 31, 2016 | 82.4% | – |
| Q3 FY2016 | Sep 30, 2016 | 80.6% | – |
| Q2 FY2016 | Jun 30, 2016 | 76.5% | – |
See a number that looks wrong?